China is a major diabetic country with over 100 million diabetic patients, ranking first in the world. CGeneTech Biomedical Technologies (Suzhou) Co., Ltd.'s clinical trial application for a Class I innovative drug, Centagliptin phosphate, for the treatment of type 2 diabetes was approved by the State Food and Drug Administration in May 2017. At present, Centec has entered into an agreement with institutions including Jiangsu Provincial People's Hospital to conduct the Phase I clinical trial of Centagliptin phosphate. Centagliptin phosphate belongs to the dipeptidyl peptidase (DPP)-4 inhibitor class, which has the greatest advantage of not causing hypoglycaemia and weight gain, and is cardiovascular protective; at the same time, Chinese patients with type 2 diabetes benefit more from DPP-4 inhibitors because they have more damaged pancreatic beta cells than those in Europe and the US, and one of the features of DPP-4 inhibitors is that they can improve beta cell damage. This has led to the increasing acceptance of DPP-4 inhibitors by doctors in China.

  Shengliptin phosphate is a new diabetes drug developed by the National 12th Five-Year Plan and Jiangsu Province's Science and Technology Support Program. The pre-clinical studies of Shengliptin phosphate have shown that it is 3-10 times more effective than the world's best drug, Selegiline phosphate (Genovate), and more than 5 times safer than Selegiline phosphate, which is a clear advantage. The successful launch of Shengliptin phosphate will bring a more affordable, safe and effective drug option to hundreds of millions of Chinese type 2 diabetes patients and will further improve the treatment of type 2 diabetes in China. Centurion will always take independent innovation as the driving force for its development, continue to undertake the mission of developing new drugs for major diseases in China, work closely with academic forces at home and abroad, and actively explore the development of China's pharmaceutical technology industrialisation for the benefit of Chinese patients.